All stock lists
Karyopharm Therapeutics Inc. (NASDAQ:KPTI)
US · Delayed Price · Currency is USD
Healthcare · Biotechnology
0.48-0.04 (-7.67%)
Insider Score
––Not scored
KPTI Insider Score
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
KPTI Income Statement
| Fiscal Period | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Period Ending | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 |
| Revenue | 33.43 M | 35.07 M | 34.08 M | 44.04 M | 37.93 M | 30.02 M |
| Revenue Growth (YoY) | -11.86 % | 16.83 % | 11.58 % | 13.57 % | -11.35 % | -9.39 % |
| Cost of Revenue | 1.08 M | 1.36 M | 1.48 M | 2.11 M | 1.05 M | 1.30 M |
| Gross Profit | 32.35 M | 33.71 M | 32.59 M | 41.93 M | 36.88 M | 28.71 M |
| SG&A Expense | 25.92 M | 26.68 M | 22.77 M | 26.61 M | 28.48 M | 27.35 M |
| R&D Expense | 29.95 M | 33.78 M | 27.67 M | 30.54 M | 32.79 M | 34.62 M |
| Operating Expenses | 54.87 M | 60.47 M | 50.44 M | 57.15 M | 61.27 M | 61.97 M |
| Operating Income | -22.53 M | -26.76 M | -17.84 M | -15.22 M | -24.39 M | -33.26 M |
| Pretax Income | -67.02 M | -22.39 M | -102.27 M | -33.09 M | -37.21 M | -23.43 M |
| Tax Provision | 0.00 | 1.00 K | -67.00 K | 34.00 K | 40.00 K | 36.00 K |
| Net Income | -67.02 M | -22.39 M | -102.20 M | -33.13 M | -37.25 M | -23.46 M |
| EPS (Basic) | -2.32 | -1.02 | -15.16 | -3.82 | -4.32 | -2.77 |
| EPS (Diluted) | -2.32 | -1.24 | -5.69 | -3.82 | -4.32 | -2.77 |
| Shares Outstanding | 28.94 M | 22.01 M | 6.74 M | 8.67 M | 8.62 M | 8.47 M |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.